'Epigenetic' drug may boost success of parp inhibitor treatment for leukemias and breast cancers

Drugs called PARP inhibitors, which sabotage cancer cells' ability to repair damage to their DNA, have shown some promise in treating human breast cancers that contain BRCA1 and BRCA2 gene mutations. Now, a new study in lab-grown cancer cells and mice suggests that their effectiveness could be strengthened and expanded to other forms of breast cancer and leukemia not linked to BRCA mutations by adding a so-called epigenetic drug.

Top News

Ain't No God; don't even think about theism

UnFox News: not a propaganda arm of the Republican party